Clinical Trial Update: Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin) [Phase 1, Phase 2]

View source ↗

Summary

This update reports results from a Phase 1/2 trial evaluating volociximab (M200) in combination with liposomal doxorubicin for ovarian cancer and primary perito…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Volociximab (M200) (volociximab)
• liposomal doxorubicin (doxorubicin liposomal)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Ovarian Cancer, Primary Peritoneal Cancer | Phase 1, Phase 2 | Status: COMPLETED